Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) Tax Provisions: 2020-2025

Historic Tax Provisions for UroGen Pharma (URGN) over the last 4 years, with Sep 2025 value amounting to -$1.1 million.

  • UroGen Pharma's Tax Provisions fell 1258.24% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year decrease of 25.64%. This contributed to the annual value of $2.8 million for FY2024, which is 27.76% down from last year.
  • Latest data reveals that UroGen Pharma reported Tax Provisions of -$1.1 million as of Q3 2025, which was down 203.84% from $1.0 million recorded in Q2 2025.
  • UroGen Pharma's Tax Provisions' 5-year high stood at $3.9 million during Q4 2023, with a 5-year trough of -$1.1 million in Q3 2025.
  • In the last 3 years, UroGen Pharma's Tax Provisions had a median value of $54,000 in 2024 and averaged $645,909.
  • Data for UroGen Pharma's Tax Provisions shows a peak YoY increase of 2,571.05% (in 2025) and a maximum YoY decrease of 1,258.24% (in 2025) over the last 5 years.
  • Quarterly analysis of 5 years shows UroGen Pharma's Tax Provisions stood at $1.1 million in 2021, then plummeted by 39.40% to $689,000 in 2022, then surged by 459.36% to $3.9 million in 2023, then slumped by 31.27% to $2.6 million in 2024, then tumbled by 1,258.24% to -$1.1 million in 2025.
  • Its last three reported values are -$1.1 million in Q3 2025, $1.0 million for Q2 2025, and $392,000 during Q1 2025.